Get started
JOHNSON & JOHNSONJOHNSON & JOHNSONJOHNSON & JOHNSON

JOHNSON & JOHNSON

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

JNJ trade ideas

Johnson & Johnson (NYSE: JNJ)_May_08_2018JNJ has had a good run since the beginning of 2017. Although, the stock price has dropped from a high of $148 to $122, I think reality is catching up with investors that equity valuations have been quite expensive and that it is time for some correction. I believe the fundamentals of the company remain strong although the liabilities with rising interest rates may be a cause for concern. I believe the current scenario presents an opportunity to short the stock. Based on the head the shoulder pattern, the price is expected to drop to $110-$115 range.
NYSE:JNJShort
by advisacorp
3
Blood Sugar Makes You HighJohnson & Johnson has been honored for its dedication to people, innovation and the health of people around the world! Therefore, A Model Company. Economically, a new blockbuster is emerging! The company has received a takeover bid for its blood glucose control business. The investment company Platinum Equity is willing to pay 2.1 billion US-Dollar for this division of the US pharmaceutical company. Our recognition - blood sugar makes you high! What has happened lately? Johnson & Johnson hit the list of the best jobs Glassdoor's 2018. The company was named to Glassdoor’s 2018 List of best places to work, based solely on the positive feedback from its employees. Additionally, Johnson & Johnson named a 2017 Fortune's Most Admired Company. However, last year's financial results were rather disappointing. Johnson & Johnson's net income for 2017 was $1.3 billion, compared to $16.5 billion a year earlier. A contributing cause for the lousy results was the tax payments of $13.6 billion required in the fourth quarter of last year. At the same time, the company's worldwide sales for the full-year 2017 grew. According to Johnson & Johnson's 2017 Full Year Earnings Report, the company announced $76.5 billion in sales in 2017, with growth reported in all three sectors: Consumer, Medical Devices and Pharmaceuticals. This is an increase of 6.3% versus 2016. What to expect from Johnson&Johnson this year? In the annual forecast for 2018, the company indicated the expected revenue of $80.6 billion to $81.4 billion. The company also announced adjusted earnings guidance for full-year 2018 of $8.00 to $8.20 per share compared to recorded $7.30 in 2017. Afterwards, as mentioned earlier, there is a lucrative takeover bid of $2.1 billion for its blood glucose control business. What do the technical analysis methods I use say? Oscillator: The RSI is around 53 - the rise above the 50 mark is reached! Price Indicator: The stock price is below the SMA200 ($136). This resistance is now to crack! Trend indicator: The MACD is currently in the positive zone. As it is seen in the chart, after the publication of the financial figures at the beginning of the year, there was a veritable consolidation. This could have currently found a bottom. The question arises: "Is a stable countermovement started now?" Now the SMA 200 (blue line at around $136) has to be overcome, after this the way to the first target (visible in the chart as a green line) is probably largely free. The risk management tool used here is the own-developed “Traffic Signals System” (TSS) and is preferably used in analyzes by Ritschy Dobetsberger. The black line in the chart: the starting price of the idea is 133.80 US-Dollar. The red line in the chart: the stop loss is lying at 125.00 US-Dollar. The green line in the chart: First goal in the idea at around 148 US-Dollar. Disclosure: "The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such. You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas."
NYSE:JNJLong
by Ritschy
JNJ Road Ahead20171017 - Product Pipeline "apalutamide (ARN-509) - Prostate cancer pre-metastatic castration-resistant" - Phase III 20171221 - U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer Apalutamide is an investigational, next-generation oral androgen receptor inhibitor that inhibits the action of androgen in prostate cancer cells, and prevents binding of androgen to the androgen receptor, and translocation of the androgen receptor to the nucleus of the cancer cell. 20180118 - with Pfizer in hot pursuit, JNJ loses a critical patent fight as it scrambles for a new prostate cancer drug OK If J&J loses this battle, it still has a late-stage drug in front of the FDA — apalutamide, or ARN-509 — it’s hoping can protect the big revenue stream it gets from Zytiga (abiraterone), an oral drug that has helped revolutionize prostate cancer treatment over the last 5 years. J&J won a priority review of apalutamide for nonmetastatic castration resistant prostate cancer, an early designation. And it’s fielding Phase III data that is slated to be revealed at the ASCO Genitourinary Cancers Symposium on February 8. The accelerated PDUFA date is in April.
NYSE:JNJLong
by ParCorn
JOHNSON & JOHNSON PULL BACK TO SUPPORT OF ITS TRIANGLE-LONGJ&J STOCK, AFTER BREAKS UP A TRIANGLE PATTERN IS PULLING BACK TO SUPPORT AT 137.25, WHICH GIVE A GOOD OPPORTUNITY TO ENTER . I AM EXPECTING THE STOCK HOLDS AT SUPPORT AND BOUNCE. THE INITIAL TARGET COULD BE 145, WHICH IS THE 200% OF FIBONACCI EXTENSION OF THE PREVIOUS LOW. HOWEVER, THE TRIANGLE CALL FOR A LONG TERM TARGET OF 151-152 MINIMUM. IF THE STOCK PRICE BREAKS SUPPORT DOWN FOR A GOOD MARGIN, THE STOP LOSS IS SET UP AT 134. THIS ANALYSIS IS FOR EDUCATION PURPOSES. GOOD LUCK!!!! www.tradingview.com
NYSE:JNJLong
by ralvizua